









Markets
/
Stocks
/
nasdaq-mist
/

Milestone Pharmaceuticals Inc

MIST



View Detailed Chart

2.075USD

-0.075-3.49%

Market hours （ET）Quotes delayed by 15 min

176.73MMarket Cap

LossP/E TTM



Milestone Pharmaceuticals Inc

2.075

-0.075-3.49%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-3.49%

5 Days

-13.90%

1 Month

-13.54%

6 Months

+22.78%

Year to Date

-12.08%

1 Year

+15.28%

View Detailed Chart

TradingKey Stock Score of Milestone Pharmaceuticals Inc

Currency: USD Updated: 2025-12-19

Key Insights

Milestone Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 135/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.75.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Milestone Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

135 / 404

Overall Ranking

257 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.750

Target Price

+40.98%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Milestone Pharmaceuticals Inc Highlights

StrengthsRisks

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

Undervalued

The company’s latest PE is -2.74, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 19.38M shares, decreasing 22.53% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.24.